Established in year 2006, Zhejiang Changming Pharmaceutical Co., Ltd specializes in research, development, production and marketing activities of API and pharmaceutical intermediates. Equipped with world top class facilities, Changming Pharmaceutical is strictly managed as per cGMP standards. The company has attained various certificates for its products and services, including Chinese GMP certificate, EU GMP certificate, US EIR Report, ISO 9001 certificate, ISO14001 certificate and OHSAS18001 certificate. Changming Pharmaceutical is one of the leading suppliers of APIs and intermediates for pharmaceutical ACE inhibitors. The company’s main products include Enalapril Maleate, Ramipril, Lisinopril Dihydrate, Benfotiamine, etc. Among these products, Changming Pharmaceutical has attained CGMP certificates for Enalapril Maleate and Doxofylline. In addition, Changming Pharmaceutical has received COS certificates for Enalapril Maleate, Ramipril, and Lisinopril Dihydrate. In the end of year 2014, Zhejiang Shengda Group invests in Changming Pharmaceutical. As the main shareholder of Changming Pharmaceutical, Zhejiang Shengda Group owns several subsidiary companies. It’s business covers areas of APIs, pharmaceutical intermediates, Bio-chemical and food&feed additives. With Shengda Group’s advantages in both wider product ranges and richer management experiences, Changming Pharmaceutical aims to provide its customers with better services. Chamngming Pharmaceutical looks forward to establishing long term cooperation with its customers at home and abroad.
